West Palm Beach, Florida-based Integra Connect, which develops information technology solutions for healthcare providers, has tracked the performance of its customers involved in the OCM program, which totals about 16 practices and 1,000 oncologists. “What we see is a steady improvement,” says Charles Saunders, MD, CEO, Integra Connect. With each successive performance period, more of the practices have kept their actual costs of care under the target cost set by CMS, he says.
A new partnership between leading precision medicine companies seeks to give patients with cancer—and their physicians—the most complete look possible at their disease by evaluating both the molecular and genetic elements.
Caris Life Sciences, a leader in somatic testing on cancer tumor cells, has joined forces with Ambry Genetics to offer its 67-gene test that evaluates a patient’s hereditary risk for cancer.
The Oncology Care Model has reached yet another major milestone, releasing its year-three results in August 2019. Though participants have shared concerns over potential weaknesses in the program, like attribution logic and novel therapy adjustment, the almost 1000 provider participants working with Integra Connect continue to find value-based cancer care an inevitable necessity as more commercial payers adopt value-based models.
After 3 years of struggling to meet targets for improved care quality and cost efficiency, many of the 175 practices that have remained in the Oncology Care Model (OCM) of the Centers for Medicare & Medicaid Services (CMS) have a decision to make: Assume a share of the downside risk for failure to meet financial targets or exit the OCM by December 3.
As fee-for-service models give way to value-based healthcare delivery models, US providers and patients alike can hopefully look forward to lower healthcare costs, increased quality of care, and improved outcomes. But what role will biosimilars have to play in value-based care? This week on the podcast, we’re speaking with Jeffrey Scott, MD, chief medical officer of Integra Connect, about this issue.
Predictive analytics systems are gaining ground in the hospice and palliative care fields as a means to identify patients in need of service earlier in the course of their illness. Providers and payers are increasingly using these systems to build their census and ensure that patients and families receive the right care at the right time.
It is known that genetic testing plays a role in the management of prostate cancer, but community practices are still trying to understand and overcome the challenges for increased adoption and find better ways to decide which patients require hereditary testing, how to utilize the test information, and when genetic counseling is needed. Raoul S. Concepcion, MD, covered this topic during a presentation at the 2019 Prostate Cancer Consensus Conference.
In the past month, the Centers for Medicare and Medicaid Services (CMS) shared the results of Oncology Care Model (OCM) performance period 4 (PP4) with participating practices. Charles Saunders, MD, chief executive officer, Integra Connect, provides a brief commentary on a surprising trend in the OCM PP4 results, considerations for practices contemplating two-sided risk, and how predictive analytics will help practices meet their bottom line moving forward.
With Oncology Care Model performance period 4 results out now, it’s a transformative point in the model in which practices that have not yet achieved a performance-based payment have to either enter 2-sided risk or leave the model. To dive into the most recent results and their implications, we spoke with Charles Saunders, MD, chief executive officer of Integra Connect.
The health care sector has undergone a shift in the way care is delivered, in the way outcomes are measured, and in how services are reimbursed. The movement has been toward more data-driven science with an emphasis on high-quality outcomes at less cost.
Payers and providers alike seek to ensure clinical decisions are based foremost on the best and latest evidence across all settings...